Tag

Johnson And Johnson

All articles tagged with #johnson and johnson

finance2 months ago•6 min saved

Five Dividend Kings Offer Steady Income Amid Market Volatility

Five US companies with over 50 years of consecutive dividend increases are highlighted as stable income sources for retirees. Procter & Gamble and Johnson & Johnson lead with long payout histories and strong cash flow, while Lowe’s, Emerson Electric, and Genuine Parts offer varying yields and growth profiles. Each company’s dividend is backed by free cash flow rather than debt, providing resilience against economic shocks. Risks include commodity costs, litigation, and corporate splits, but overall, these stocks aim to deliver reliable returns with low volatility.

via 24/7 Wall St.|

#dividend-kings #finance #genuine-parts

business3 months ago•191 min saved

J&J Proposes $5.5B Settlement to End Decade-Long Talc Litigation

Johnson & Johnson has proposed a $5.5 billion settlement to resolve approximately 76,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. The deal, which requires acceptance by 95% of claimants, would pay $3 billion in 2027 with remaining funds disbursed after 2028. While J&J maintains the claims lack scientific merit, plaintiffs' attorneys describe the agreement as a fair resolution after years of legal battles and failed bankruptcy attempts.

via CNN|

#business #corporate-litigation #johnson-and-johnson

business3 months ago•0 min saved

J&J to Pay $5.5B to End Talc Litigation After Court Wins

Johnson & Johnson has proposed a $5.5 billion settlement to resolve approximately 76,000 lawsuits alleging its talc products caused ovarian cancer. The deal, which requires 95% claimant participation, follows recent court victories for the company and aims to end a decade-long legal battle. Initial payments of up to $3 billion are due in 2027, with no further payments until 2028.

via ABC News - Breaking News, Latest News and Videos|

#business #johnson-and-johnson #legal

courts-news3 months ago

J&J Proposes $5.5 Billion Settlement to End US Talc Cancer Litigation

Johnson & Johnson has proposed a $5.5 billion settlement to resolve approximately 69,000 US lawsuits alleging its discontinued talc-based baby powder caused ovarian cancer. The deal, which requires acceptance by 95% of claimants, follows a recent court ruling that plaintiffs failed to prove specific causation. While J&J denies the product causes cancer, it has already halted global sales of talc-based powder. A separate, massive UK case involving over 7,000 claimants remains pending and is not covered by this agreement.

via Al Jazeera|

#courts-news #johnson-and-johnson #ovarian-cancer

business3 months ago•1 min saved

J&J Proposes $5.5bn Settlement to End Talc Litigation

Johnson & Johnson has proposed a $5.5 billion settlement to resolve approximately 69,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. The deal, which requires 95% claimant approval, follows a recent court ruling questioning plaintiffs' ability to prove specific causation. While J&J denies the products cause cancer, the settlement aims to end a 15-year legal battle. The agreement excludes a separate, massive UK case involving over 7,000 claimants.

via BBC|

#business #consumer-health #johnson-and-johnson

business4 months ago•19 min saved

Healthcare Leaders Rally to Fresh Highs as Lilly, J&J and AbbVie Soar

Healthcare stocks outperformed the broader market as Eli Lilly (LLY), Johnson & Johnson (JNJ) and AbbVie (ABBV) hit fresh 52-week highs (with Merck near highs), while biotech names like Moderna led rallies; the Health Care Select Sector SPDR ETF XLV has climbed about 3% year-to-date, signaling renewed investor interest in defensive healthcare plays amid ongoing M&A activity.

via Yahoo Finance|

#business #eli-lilly #healthcare

personal-finance4 months ago•23 min saved

Patience Pays: Turning $500K Into a Six-Figure Dividend Income

Turning $500,000 into a six-figure inflation‑adjusted dividend income isn’t about chasing the highest yield. It’s about blending modest, durable yields with steady dividend growth to compound over 20–30 years. The piece lays out three paths: a conservative 3.5% yield with 7% annual growth (e.g., Johnson & Johnson, Procter & Gamble) could reach about $130k by year 30; a 5% yield portfolio (Realty Income) offers earlier cash but slower compounding; and a high-yield, durability‑conscious 10% yield (AGNC) carries greater risk to principal. It emphasizes total returns, tax considerations, reinvesting dividends, and patience to grow income over time.

via 24/7 Wall St.|

#compounding #dividend-growth #johnson-and-johnson

health4 months ago•5 min saved

J&J CEO projects cancer elimination within a decade through immunotherapy breakthroughs

At the WSJ Leadership Institute summit, Johnson & Johnson CEO Joaquin Duato said the company aims to eliminate cancer within 10 years, citing breakthroughs in immunotherapy that have extended remission in multiple myeloma and improved longevity, with AI and biomarkers enabling earlier diagnosis and more personalized treatments. He suggested some cancers could be cured while others become chronic, and noted J&J's acquisitions like Firefly Bio to target difficult mutations, alongside advances such as a melanoma vaccine study by Merck and Moderna that underscores rapid progress in oncology.

via Fox News|

#cancer-cure-timeline #cancer-research #health

business5 months ago•5 min saved

J&J Expands U.S. Vision Manufacturing with a $1B Jacksonville Investment

Johnson & Johnson announced a more than $1 billion investment in Jacksonville, Florida to scale U.S.-based Vision manufacturing, packaging, and a new distribution facility as part of a $55 billion U.S. investment through 2029. The upgrades aim to boost ACUVUE contact lens production for about 40 million patients, support 3,500 local jobs, and strengthen supply chain resilience, with the facility slated to be fully operational in 2028 and Florida’s economy benefiting from an estimated $6 billion annual impact.

via Johnson & Johnson|

#acuvue #business #jacksonville

business5 months ago•2 min saved

J&J makes a $1B bet on degrader antibody conjugates with Firefly Bio

Johnson & Johnson is paying $1 billion upfront to acquire Firefly Bio and its Firelink degrader antibody conjugate (DAC) platform, gaining a technology that links catalytic protein degraders to antibodies to target KRAS-driven tumors and expand its innovative medicine pipeline. Firefly has shown preclinical tumor reductions at very low doses, and the deal underscores rising pharma interest in DACs, which are drawing attention after multiple partnerships and acquisitions in the space.

via Fierce Biotech|

#business #degrader-antibody-conjugates #firefly-bio

science5 months ago•34 min saved

Cancer drug erases tumors in chemo-resistant cancers, early trial results show

In a multi-country trial, Johnson & Johnson’s amivantamab shrank or eradicated tumors in patients with head and neck cancer (and some lung cancers) that had stopped responding to chemotherapy or immunotherapy; 43 of 102 patients responded (28 partial shrinkages, 15 complete disappearances), with results to be presented at ASCO in Chicago; the drug works by targeting tumor growth proteins and activating the immune system, and median survival was about 12.5 months, with ongoing trials to explore broader use.

via Yahoo News Canada|

#amivantamab #cancer #head-and-neck-cancer

health7 months ago•9 min saved

Lancet retracts 1977 unsigned talc commentary after uncovering Johnson & Johnson ties

The Lancet has retracted a 1977 unsigned commentary on cosmetic talc after discovering the author was a paid Johnson & Johnson consultant, revealing an undeclared conflict of interest; editors say such unsigned pieces would not be published today, and the decision comes amid decades of talc-related litigation and ongoing debates over asbestos testing in cosmetics, including a FDA rule proposal later withdrawn in 2025.

via Retraction Watch|

#conflicts-of-interest #health #johnson-and-johnson

healthcare8 months ago•2 min saved

J&J’s new psoriasis pill could reshape the treatment landscape

Johnson & Johnson won U.S. approval for Icotyde, a daily oral medication for moderate-to-severe plaque psoriasis in patients 12 and older, designed to mimic the effects of top-selling injectables like Skyrizi and Tremfya without injections. The pill could expand the patient market and is projected to reach more than $5 billion in peak annual sales, potentially reshaping competition in a multibillion-dollar field.

via statnews.com|

#fda-approval #healthcare #icotyde

business8 months ago•4 min saved

J&J Bets Big on U.S. Cell-Therapy Manufacturing with $1B Pennsylvania Facility

Johnson & Johnson announced more than a $1 billion investment to build a next-generation cell-therapy manufacturing facility in Lower Gwynedd, Montgomery County, Pennsylvania, expanding U.S. manufacturing capacity, creating 500+ biomanufacturing jobs and up to 4,000 construction roles, as part of a broader $55 billion U.S. investment through 2029 to advance cancer, immune-mediated, and neurological therapies.

via Johnson & Johnson|

#biomanufacturing #business #cell-therapy

business-news8 months ago•53 min saved

Johnson & Johnson to invest over $1B in a new cell-therapy facility in Lower Gwynedd

Johnson & Johnson announced a more-than-$1 billion plan to build a next-generation cell-therapy manufacturing facility on a 154-acre site in Spring House, Lower Gwynedd, to expand U.S. manufacturing for cancer, immune-mediated and neurological diseases. The project is expected to create about 4,000 construction jobs and 500 skilled biomanufacturing roles; J&J already operates a large facility in the area with about 2,500 workers. Pennsylvania officials welcomed the investment as a boost to the state's life sciences and workforce.

via Around Ambler|

#business-news #investment #johnson-and-johnson